Sage Therapeutics (SAGE) ~45% Upside Does Not Nearly Reflect Potential Market Opportunity - RBC

RBC Capital analyst Brian Abrahams weighed in on Sage Therapeutics (NASDAQ: SAGE) following a Q&A session hosted by management, which the analyst noted offered mostly incremental tidbits, and overall supports their comfort and enthusiasm around efficacy/safety of ‘217 in PPD and beyond.

The data/comments reaffirms their view that with continued strong study conduct and the right allocation of investments, SAGE has a high (and growing) likelihood of bringing a game-changing $4B + opportunity antidepressant to the market.

"We remain buyers into strength, as we believe even following today’s ~45% upside, the company’s $7.7B market does not nearly reflect this potential market opportunity," he added.

The firm maintained an Outperform rating and price target of $255 on SAGE.

For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.

Shares of Sage Therapeutics closed at $97.51 yesterday.

You May Also Be Interested In

• Williams-Sonoma (WSM) PT Raised to $260 at RBC Capital
• UBS Reiterates Buy Rating on HF Sinclair (DINO)
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS